Strategic Signals Weekly

Aldeyra Therapeutics received a Complete Response Letter (CRL) from the FDA on March 16, 2026, denying approval of its New Drug Application for reproxalap for dry eye disease. Following a Type D meeting, Aldeyra plans to submit a Formal Dispute Resolution Request (FDRR) in Q4 2026 to appeal the CRL. The company also announced an extension of its operational cash runway into 2029.

Drug: reproxalap · Indication: dry eye disease

Adagio Medical Holdings, Inc. is exploring strategic alternatives and, in connection with this process, lowered the conversion price of its 13% Senior Secured Convertible Notes. Between September 25 and October 1, 2026, a noteholder converted $776,111 in principal amount of these notes, resulting in the issuance of 4,978,869 shares of common stock at prices ranging from $0.1265 to $0.1618 per share. These shares were issued under an exemption from registration for exchanges of outstanding securities.

Keros Therapeutics, Inc. announced it will receive a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., Inc. This payment is triggered by the dosing of the first patient in the Phase 3 ELRiSE MF clinical trial for elritercept. The trial will evaluate elritercept's efficacy and safety against placebo in patients with myelofibrosis and anemia who are on concurrent ruxolitinib therapy.

Drug: elritercept · Indication: myelofibrosis and anemia · Partner: Takeda Pharmaceuticals U.S.A., Inc.

Heron Therapeutics, Inc. has entered into a multi-product Development and License Agreement with Long Grove Pharmaceuticals, LLC. Under this agreement, Heron gains exclusive rights to import, distribute, sell, and market certain products from Long Grove in the U.S. Heron will pay regulatory and sales-based milestone payments, along with royalties, but no upfront payment was disclosed.

Partner: Long Grove Pharmaceuticals, LLC

Sagimet Biosciences Inc. entered into an underwriting agreement for a public offering of common stock and pre-funded warrants, expecting to generate net proceeds of $107.5 million. The company plans to use these funds, along with existing cash, to finance a Phase 3 clinical trial for denifanstat in acne, support pre-launch activities for denifanstat, advance TVB-3567 through Phase 2 topline results, and progress its topical FASN inhibitor program to IND submission.

ENDRA Life Sciences Inc. amended its merger agreement with ASP Isotopes Inc., revising the minimum cash closing condition to approximately $3.8 million and removing classified board provisions. The amendments also increased Renergen's (an ASPI subsidiary) borrowing capacity from ASPI from $80 million to up to $200 million. Additionally, ENDRA and an ASP Affiliate amended previously issued warrants, removing a 4.99% beneficial ownership limitation on the ASP Affiliate's ability to exercise them.

Pyxis Oncology, Inc. completed an underwritten public offering, raising approximately $102.8 million in net proceeds. The offering included common stock, pre-funded warrants, and common warrants. The company plans to use these proceeds to advance its lead clinical program, micvotabart pelidotin (MICVO), through key milestones, including a planned Phase 3 trial for second-line and later recurrent or metastatic head and neck squamous cell carcinoma.

Lantern Pharma Inc. completed a registered direct offering and a concurrent private placement, raising approximately $4.0 million in gross proceeds. The offering involved the sale of common shares and pre-funded warrants, while the private placement included warrants to purchase additional common stock, contingent on stockholder approval. The company plans to use the net proceeds for working capital and general corporate purposes.

Solana Company announced a registered direct offering of 4,369,356 shares of its Class A common stock and warrants to purchase an equal number of shares, priced at $3.433 per share. The offering is expected to generate gross proceeds of approximately $15 million, with net proceeds of about $14.3 million. The company plans to use these funds for working capital, general corporate purposes, business expansion, and other strategic initiatives.